Castle Biosciences, Inc. (CSTL) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #1 (Strong Buy). This upgrade is essentially a reflection of an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and follo ...

Castle Biosciences, Inc. (NASDAQ:CSTL) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Camilla Zuckero - VP, IR and Corporate Affairs Derek Maetzold - Founder, President and CEO Frank Stokes - CFO Conference Call Participants Kyle Mikson - Canaccord Genuity Corey Rosenbaum - Scotiabank Thomas Flaten - Lake Street Mason Carrico - Stevens Puneet Souda - Leerink Partners Paul Knight - KeyBanc Operator Good afternoon, and welcome to Castle Biosciences Third Quarter 2024 Confere ...

Castle Biosciences, Inc. (CSTL) came out with quarterly earnings of $0.08 per share, beating the Zacks Consensus Estimate of a loss of $0.06 per share. This compares to loss of $0.26 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 233.33%. A quarter ago, it was expected that this company would post a loss of $0.16 per share when it actually produced earnings of $0.31, delivering a surprise of 293.75%.Over the last four quarter ...

Empowering people, informing care decisions ©2024 Castle Biosciences 1 Third Quarter 2024 November 4, 2024 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are subject to the "safe harbor" created by those sections. These forward-looking statements include, but are not limited to, statements concerning: our position ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _________ to _________ Commission File Number: 001-38984 CASTLE BIOSCIENCES, INC. (Exact name of registrant as specified in its charter) ...

Exhibit 99.1 Castle Biosciences Reports Third Quarter 2024 Results Q3 2024 revenue increased 39% over Q3 2023 to $86 million Q3 2024 total test reports increased 41% over Q3 2023 Raising full-year 2024 revenue guidance to $320-330 million from $275-300 million Conference call and webcast today at 4:30 p.m. ET FRIENDSWOOD, Texas - Nov. 4, 2024--Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the th ...

Core Viewpoint - Castle Biosciences, Inc. has experienced significant stock performance, with a 22% increase over the past month and a 60.7% rise since the beginning of the year, outperforming the broader medical sector and the biomedical and genetics industry [1][2]. Performance Metrics - The company has consistently exceeded earnings expectations, reporting an EPS of $0.31 against a consensus estimate of -$0.16 in its latest earnings report [2]. - For the current fiscal year, Castle Biosciences is projected to have an EPS of -$0.59 on revenues of $299.8 million, reflecting a 72.43% change in EPS and a 36.41% change in revenues [3]. - The next fiscal year forecasts an EPS of -$2.15 on revenues of $279.54 million, indicating a year-over-year change of -265.25% in EPS and -6.76% in revenues [3]. Valuation Metrics - The stock is currently at a 52-week high, prompting a review of valuation metrics to assess future performance potential [4]. - Castle Biosciences has a Value Score of C, a Growth Score of A, and a Momentum Score of F, resulting in a combined VGM Score of B [6]. Zacks Rank - The stock holds a Zacks Rank of 2 (Buy), supported by rising earnings estimates, indicating potential for further gains [7].

While "the trend is your friend" when it comes to short-term investing or trading, timing entries into the trend is a key determinant of success. And increasing the odds of success by making sure the sustainability of a trend isn't easy.Often, the direction of a stock's price movement reverses quickly after taking a position in it, making investors incur a short-term capital loss. So, it's important to ensure that there are enough factors -- such as sound fundamentals, positive earnings estimate revisions, ...

Momentum investing is all about the idea of following a stock's recent trend, which can be in either direction. In the 'long' context, investors will essentially be "buying high, but hoping to sell even higher." And for investors following this methodology, taking advantage of trends in a stock's price is key; once a stock establishes a course, it is more than likely to continue moving in that direction. The goal is that once a stock heads down a fixed path, it will lead to timely and profitable trades.Whil ...

Have you been paying attention to shares of Castle Biosciences, Inc. (CSTL) ? Shares have been on the move with the stock up 10.7% over the past month. The stock hit a new 52-week high of $34.49 in the previous session. Castle Biosciences, Inc. has gained 58.8% since the start of the year compared to the 8.6% move for the Zacks Medical sector and the -0.2% return for the Zacks Medical - Biomedical and Genetics industry. What's Driving the Outperformance? The stock has a great record of positive earnings sur ...